CP-547,632 and Chemotherapy Combination for Advanced Non-Small Cell Lung Cancer Treatment

This study explores the effectiveness of an oral medication, CP-547,632, in combination with standard chemotherapy for treating advanced stage non-small cell lung cancer. The medication, CP-547,632, is a type of drug known as a tyrosine kinase inhibitor, specifically targeting VEGFR-2. The goal is to determine if this combination therapy offers improved outcomes compared to chemotherapy alone for individuals with this form of lung cancer. Participants in this study receive either the combination of CP-547,632 and chemotherapy (carboplatin and paclitaxel), or just the chemotherapy. The study's primary focus is to evaluate if the addition of CP-547,632 to chemotherapy leads to better results. However, it's important to note that the study was discontinued due to statistical estimates suggesting a low likelihood of positive outcomes if it continued to the next stage.